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Cutaneous squamous cell carcinomas (SCCs) and basal cell carci-
nomas (BCCs), classified together as nonmelanoma skin cancers, 
are  the  most  common  malignancies  in  the  United  States  (1). 
Although it is uncommon for these cancers to metastasize, they are 
responsible for considerable morbidity and represent a substantial 
economic  burden  to  the  health-care  system.  The  direct  cost  of 
treatment for nonmelanoma skin cancers in the United States has 
been estimated to exceed $1.4 billion annually (2). The incidence of 
nonmelanoma skin cancers, unlike that of many other malignancies, 
has been increasing (3,4), and these cancers are beginning to occur 
more frequently in younger people (5).
Because most cutaneous SCCs and BCCs are thought to be 
caused by excessive exposure to ultraviolet (UV) radiation (6–8), 
there has been a concerted effort by various health-care organiza-
tions to educate the public about the hazards of overexposure to 
the sun and artificial UV light sources. Actions that have been 
advocated include the use of protective clothing and hats, avoid-
ance  of  outdoor  activities  during  peak  hours  of  sun  exposure, 
ARTICLE
Chemoprevention of Nonmelanoma Skin Cancer With 
Celecoxib: A Randomized, Double-Blind, Placebo-Controlled 
Trial
Craig A. Elmets, Jaye L. Viner, Alice P. Pentland, Wendy Cantrell, Hui-Yi Lin, Howard Bailey, Sewon Kang, Kenneth G. Linden, 
Michael Heffernan, Madeleine Duvic, Ellen Richmond, Boni E. Elewski, Asad Umar, Walter Bell, Gary B. Gordon
Manuscript received January 7, 2010; revised September 13, 2010; accepted October 8, 2010.
Correspondence to: Craig A. Elmets, MD, Department of Dermatology, 1530 3rd Ave South, EFH 414, University of Alabama at Birmingham, Birmingham, 
AL 35294 (e-mail: celmets@uab.edu).
  Background  Preclinical studies indicate that the enzyme cyclooxygenase 2 plays an important role in ultraviolet-induced skin 
cancers. We evaluated the efficacy and safety of celecoxib, a cyclooxygenase 2 inhibitor, as a chemopreventive 
agent for actinic keratoses, the premalignant precursor of nonmelanoma skin cancers, and for nonmelanoma 
skin cancers, including cutaneous squamous cell carcinomas (SCCs) and basal cell carcinomas (BCCs).
  Methods  A double-blind placebo-controlled randomized trial involving 240 subjects aged 37–87 years with 10–40 actinic 
keratoses was conducted at eight US academic medical centers. Patients were randomly assigned to receive 
200 mg of celecoxib or placebo administered orally twice daily for 9 months. Subjects were evaluated at 3, 6, 9 
(ie, completion of treatment), and 11 months after randomization. The primary endpoint was the number of new 
actinic keratoses at the 9-month visit as a percentage of the number at the time of randomization. In an intent-
to-treat analysis, the incidence of actinic keratoses was compared between the two groups using t tests. In ex-
ploratory analyses, we evaluated the number of nonmelanoma skin cancers combined and SCCs and BCCs 
separately per patient at 11 months after randomization using Poisson regression, after adjustment for patient 
characteristics and time on study. The numbers of adverse events in the two treatment arms were compared 
using x2 or Fisher exact tests. All statistical tests were two-sided.
  Results  There was no difference in the incidence of actinic keratoses between the two groups at 9 months after random-
ization. However, at 11 months after randomization, there were fewer nonmelanoma skin cancers in the cele-
coxib arm than in the placebo arm (mean cumulative tumor number per patient 0.14 vs 0.35; rate ratio [RR] = 
.43, 95% confidence interval [CI] = 0.24 to 0.75; P = .003). After adjusting for age, sex, Fitzpatrick skin type, his-
tory of actinic keratosis at randomization, nonmelanoma skin cancer history, and patient time on study, the 
number of nonmelanoma skin cancers was lower in the celecoxib arm than in the placebo arm (RR = 0.41, 95% 
CI = 0.23 to 0.72, P = .002) as were the numbers of BCCs (RR = 0.40, 95% CI = 0.18 to 0.93, P = .032) and SCCs 
(RR = 0.42, 95% CI = 0.19 to 0.93, P = .032). Serious and cardiovascular adverse events were similar in the two 
groups.
  Conclusions  Celecoxib may be effective for prevention of SCCs and BCCs in individuals who have extensive actinic damage 
and are at high risk for development of nonmelanoma skin cancers.
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construction of permanent shade structures in outdoor areas, and 
the liberal and frequent application of sunscreens (9,10). However, 
sunscreens may not completely protect against SCCs, and there is 
limited  evidence  that  they  reduce  the  incidence  of  BCCs  (11). 
Thus, attempts have been made to identify alternative forms of 
chemoprevention for sunlight-induced skin cancers.
A number of chemopreventive agents for nonmelanoma skin 
cancer have been examined, including retinoids (12), oral difluoro-
methylornithine (13), topically applied DNA repair enzymes (14), 
and low-fat diets (15,16). In addition, evidence from experimental 
and  epidemiological  studies  suggests  that  cyclooxygenase  2,  an 
enzyme involved in prostaglandin synthesis, may be involved in the 
pathogenesis of nonmelanoma skin cancers (17–24). On the basis 
of evidence that cyclooxygenase 2 may be involved in UV-induced 
nonmelanoma skin cancers (17–22), we conducted a clinical trial to 
examine whether oral administration of celecoxib, a nonsteroidal 
anti-inflammatory drug (NSAID) that is an inhibitor of cyclooxy-
genase 2, would be an effective chemopreventive agent in individ-
uals who had evidence of substantial UV damage and therefore 
were at increased risk for development of additional actinic kera-
toses and/or nonmelanoma skin cancers. Based on the evidence 
from animal models that treatment with celecoxib inhibits the de-
velopment of UV-induced premalignant skin papillomas, which 
are  thought  to  correspond  to  actinic  keratoses  in  humans,  and 
results of immunohistochemical studies in humans indicating that 
COX-2 is expressed in actinic keratoses (17–22), the primary end-
point of the trial was the number of new actinic keratoses at month 
9 after randomization as a percentage of those at randomization. 
Patients were treated with celecoxib or placebo for 9 months and 
followed up for an additional 2 months. In exploratory analyses, we 
also evaluated the number of nonmelanoma skin cancers over the 
same period.
Participants and Methods
Study Design
We  conducted  a  randomized,  double-blind,  placebo-controlled 
phase II–III clinical trial to assess whether oral administration of 
celecoxib reduces the incidence of actinic keratoses, BCCs, and 
cutaneous SCCs in individuals who were at high risk for these le-
sions (25,26). Patients were considered to be at high risk based on 
the reports from other studies which showed that individuals with 
large numbers of actinic keratoses and Fitzpatrick sun reactive skin 
types I, II, or III are at increased risk of developing nonmelanoma 
skin cancers. The clinical trial was registered at clinicaltrials.gov 
(NCT0027976).  Eight  study  sites  in  the  United  States  partici-
pated: the University of Alabama at Birmingham (Birmingham, 
AL); the University of Rochester School of Medicine and Dentistry 
(Rochester, NY); the University of Wisconsin–Madison (Madison, 
WI); the University of Michigan (Ann Arbor, MI); the University 
of California, Irvine (Irvine, CA); Washington University School 
of  Medicine  (St  Louis,  MO);  the  University  of  Texas  M.D. 
Anderson  Cancer  Center  (Houston,  TX);  and  Northwestern 
University (Chicago, IL). The study began on January 18, 2001, 
and completed on November 3, 2006, at which time the Food and 
Drug  Administration  (FDA)  requested  termination  of  this  trial 
after preliminary data from another trial (27) showed an associa-
tion between another cyclooxygenase 2 inhibitor and cardiovascu-
lar adverse events. The protocol was approved by the institutional 
review board at each participating site, and all participants gave 
written informed consent. The trial was a cooperative effort of the 
participating  sites,  the  National  Cancer  Institute  (NCI),  and 
Pfizer,  Inc  (New  York,  NY)  (the  manufacturer  of  celecoxib 
[Celebrex]) through a clinical trials agreement with the NCI’s 
Division of Cancer Prevention.
Study Population
Individuals were eligible to participate if they were at least 18 years 
old and had a Fitzpatrick sun reactive skin type of I, II, or III. All 
subjects were required to have 10–40 actinic keratoses on the upper 
extremities, neck, face, and scalp at the time of entry into the study, 
and a previous histological diagnosis of at least one actinic keratosis 
and/or nonmelanoma skin cancer. On the basis of these inclusion 
criteria, subjects were considered to be at high risk for nonmela-
noma skin cancers (25,26). Individuals with more than 40 actinic 
keratoses were excluded because of technical difficulties involved in 
mapping  that  many  lesions.  Subjects  were  not  allowed  to  take 
CONTEXT AND CAVEATS
Prior knowledge
Preclinical and epidemiological data suggest that cyclooxygenase 
2 is involved in the pathogenesis of nonmelanoma skin cancers. In 
animal models, treatment with the cyclooxygenase 2 inhibitor cele-
coxib inhibits the development of ultraviolet-induced premalignant 
skin papillomas, which are thought to correspond to actinic kera-
toses (the premalignant precursor of nonmelanoma skin cancers) 
in humans.
Study design
A randomized, placebo-controlled, double-blind trial designed to 
evaluate the efficacy and safety of celecoxib, a cyclooxygenase 2 
inhibitor,  as  a  chemopreventive  agent  for  actinic  keratoses  in 
patients  with  extensive  actinic  keratoses.  Additional  exploratory 
analyses  examined  the  development  of  two  types  of  nonmela-
noma  skin  cancers,  cutaneous  squamous  cell  carcinomas  and 
basal cell carcinomas (BCCs).
Contribution
At 9 months after randomization, there was no difference in the 
incidence of new actinic keratoses between the two groups, the 
primary endpoint. Compared with placebo, celecoxib administered 
for 9 months was highly effective in preventing nonmelanoma skin 
cancers in subjects who had large numbers of actinic keratoses.
Implications
Celecoxib was not effective in preventing new actinic keratoses, 
but the study results raise the hypothesis that it may prevent some 
nonmelanoma skin cancers in patients who have actinic keratoses 
and thus are at high risk for the disease.
Limitations
The development of nonmelanoma skin cancers was not a primary 
or secondary endpoint of this trial. All participants in this study had 
extensive actinic damage. It is unclear whether celecoxib would 
have the same effect in subjects with less or no actinic damage.
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NSAIDs  or  doses  of  aspirin  more  than  81  mg/day  at  any  time 
during the study and in the 30 days before randomization or use 
any  topical  medications  during  the  study  with  the  exception  of 
emollients and sunscreens, which were allowed and recommended.
Exclusion criteria included having a known photosensitivity 
disorder; use of topical corticosteroids, alpha-hydroxyacids, or 
retinoids within 14 days before random assignment; use of oral 
or  intravenous  corticosteroids  for  more  than  two  consecutive 
weeks during the 6 months before randomization; use of inhaled 
corticosteroids  for  more  than  4  weeks  during  the  6  months 
before randomization and/or the use of nasally inhaled cortico-
steroids in the month before randomization; use of psoralens, 
cryotherapy to target skin lesions, immunotherapy, retinoids, or 
radiation  therapy  within  30  days  of  randomization;  or  laser 
resurfacing,  dermabrasion,  or  chemical  peels  within  60  days 
before randomization. Subjects were excluded if they had been 
treated with topical 5-fluorouracil within 3 months of randomi-
zation  or  with  other  forms  of  topical  chemotherapy  or  local   
radiotherapy  to  the  areas  being  studied  within  6  months  of 
randomization.
Study Treatment
Participants were screened for inclusion and exclusion criteria and 
the number of actinic keratoses. Two weeks later, they were ran-
domly assigned to receive 200 mg of celecoxib or placebo orally 
twice daily. Randomization was performed by a block randomiza-
tion procedure that was stratified for each center in blocks of four 
treatment  assignments.  Study  medications  were  administered 
through month 9 after randomization, at which time they were 
discontinued, and the subjects were followed up for two additional 
months. Subjects were evaluated for chemopreventive efficacy and 
safety at months 3, 6, 9, and 11 after randomization. At each visit, 
actinic  keratoses  were  counted  on  the  upper  extremities,  neck, 
face, and scalp. A clear plastic template was placed over each ana-
tomical site on which actinic keratoses were counted and the loca-
tion of each actinic keratosis was recorded by a study investigator 
on the plastic template. Separate plastic templates were  used at 
each visit, and the person who recorded the lesions had no knowl-
edge of or access to earlier results for that subject. At the end of 
the study, we compared the location of actinic keratoses on the 
plastic  template  map  from  months  3,  6,  9,  and  11  with  the 
one prepared at randomization to identify the number of new, 
persistent, and regressed actinic keratoses. On clinical examina-
tion, lesions that appeared as discrete scaling or keratotic patches, 
often with erythema and a sandpaper-like scale, were considered 
actinic keratoses. Lesions that did not have these clinical charac-
teristics of an actinic keratosis were not recorded on the plastic 
maps. At randomization, 32 lesions suspected of being actinic ker-
atoses  were  biopsied  and  analyzed  histologically,  of  which  28 
(88%) were confirmed to be actinic keratoses, an accuracy rate 
that  is  consistent  with  other  reports  in  the  literature  (28–32). 
Actinic keratoses were not treated at baseline or during the entire 
duration of the study. Lesions suspected of being BCC or SCC 
were biopsied, examined histologically, and, if found to be skin 
cancers by histopathologic examination, were managed by surgical 
removal.  Adverse  events  were  graded  according  to  the  NCI 
Common Toxicity Criteria (33).
Statistical Analysis
The sample size calculation was based on information from pre-
vious studies that examined the effects of sunscreens on the inci-
dence  of  actinic  keratoses  (28,34);  those  studies  used  Poisson 
models to model the number of new actinic keratoses as the per-
centage of the number at randomization for both users and nonus-
ers  of  sunscreen.  With  120  subjects  per  treatment  arm  and 
assuming a 20% dropout rate, a simulation modeling based on 
1000 replications showed that this study had approximately 95% 
power at a two-sided statistical significance level of .05 to detect a 
40% relative reduction in the number of new actinic keratoses at 
the final visit (month 9 visit) as the percentage of randomization in 
the celecoxib-treated group compared with the placebo group.
Analyses were performed on the per-protocol and the intention-
to-treat populations for all subjects who were randomly assigned 
to a study arm and who had at least one follow-up visit after base-
line. Compliance with study medications was monitored by pill 
counts at each visit. Subjects who had taken more than 80% of 
their pills were considered to be compliant, a compliance figure 
that is consistent with that used in another clinical chemopreven-
tion trial of NSAIDs in BCC (35). In addition, subjects who failed 
to  present  for  clinic  follow-up  on  two  consecutive  visits  were 
withdrawn from the study. Patients’ baseline characteristics were 
compared for the two treatment arms (celecoxib vs placebo) using 
the t test for continuous variables and the x
2 or Fisher exact test 
for categorical variables. We used the same univariate analytical 
methods to compare the baseline characteristics for subjects who 
completed and withdrew from the study, stratified by treatment 
arm.
The two treatment arms were compared for the mean values of the 
following measures using t tests: the total number of actinic keratoses 
at randomization, the total number of actinic keratoses at the com-
pletion of therapy (ie, month 9), the number of new actinic keratoses 
at the completion of therapy, the ratio of new actinic keratoses at 
the completion of therapy to the number of actinic keratoses at 
randomization, and the ratio of the total number of actinic keratoses 
at the completion of therapy to the number at randomization. The 
effect of celecoxib on the ratio of new actinic keratoses at the 
completion of therapy to the number of actinic keratoses at random-
ization was also evaluated using a Poisson regression model that 
controlled for age, sex (male/female), sunscreen use (yes/no), and 
Fitzpatrick skin type (I, II, or III) (25,26).
The mean cumulative number of nonmelanoma skin cancers, 
BCCs, and SCCs per patient at months 3, 6, 9, and 11 (or at the 
time of withdrawal) and their 95% confidence intervals (CIs) were 
calculated  based  on  the  Poisson  distribution.  The  difference 
between study arms in the mean cumulative number of tumors at 
each  visit  (or  at  the  time  of  withdrawal)  was  evaluated  using 
Poisson regression, adjusting for patient on-study time. The cele-
coxib treatment effect was also evaluated after adjusting for age, 
sex (male/female), Fitzpatrick skin type (I, II, or III), actinic kera-
tosis  history  at  randomization  (yes/no),  skin  cancer  history  at 
baseline (yes/no), and time on study.
The safety analysis included all randomly assigned patients who 
took at least one dose of study medicine. The numbers of adverse 
events in the two treatments arms were compared using x
2 or Fisher 
exact tests. All statistical analyses (including univariate tests and 1838   Articles | JNCI  Vol. 102, Issue 24  |  December 15, 2010
Poisson regressions) were performed using SAS version 9.0 soft-
ware (SAS Institute, Cary, NC). A P value less than .05 was consid-
ered statistically significant. All statistical tests were two-sided.
Results
Between January 18, 2001, and November 3, 2006, 240 patients 
were randomly assigned to treatment with celecoxib 200 mg twice 
daily  or  placebo.  There  were  122  participants  in  the  celecoxib 
group and 118 in the placebo group (Table 1). Participants ranged 
in age from 37.5 years to 87.6 years at enrollment. Specifically, the 
mean age of the participants was 65.2 years (SD = 10.2 years), all 
participants  had  evidence  of  extensive  actinic  damage  and  a 
Fitzpatrick skin type of I, II, or III, and the average number of 
previous skin cancers was 2.3 (SD = 4.2). Of the 240 individuals 
who entered the study, 183 completed it, including 87 (71%) of 
those randomly assigned to celecoxib and 96 (81%) of those ran-
domly assigned to placebo (Figure 1). The reasons participants 
withdrew from the trial are shown in Figure 1. The major differ-
ences between the celecoxib and placebo groups in reasons for 
participant withdrawal were withdrawal of consent (seven vs one 
participant, respectively) and termination of the study by the FDA 
(12 vs six participants, respectively). The main reason participants 
gave for withdrawing consent was the prohibition on taking pain 
medications  for  arthritis.  The  FDA  terminated  the  study  early 
after preliminary data from another study showed an association 
between another cyclooxygenase 2 inhibitor (27) and an increased 
risk of cardiovascular adverse events because of concerns that the 
increased risk might extend to celecoxib, the cyclooxygenase 2 in-
hibitor used in this study. At the time that this study was termi-
nated, there were more subjects in the celecoxib arm of the study 
than in the placebo arm (12 vs six participants, respectively).
Efficacy of Treatment
We performed separate analyses to examine whether treatment 
with celecoxib influenced the number of actinic keratoses after 3, 
6, and 9 months of therapy and at 2 months following the comple-
tion of therapy (ie, month 11). Specifically, we assessed the total 
number of actinic keratoses, the number of new actinic keratoses, 
and the ratio of total lesions to the number at baseline for the body 
as a whole and for the upper extremities, neck, face, and scalp in-
dividually. For each of these analyses, there was no difference in 
any of these measures between the celecoxib and placebo arms at 
month 9 (Table 2) or month 11 (data not shown) after randomiza-
tion. After controlling for age, sex, sunscreen use, and Fitzpatrick 
skin type using Poisson regression, the ratio of new lesions to the 
number at randomization did not differ statistically significantly 
between the celecoxib and placebo groups (P = .69). A total of 
29.3% of the actinic keratoses in both treatment groups regressed 
spontaneously, consistent with other reports (36,37).
Table 1. Baseline characteristics of participants at screening
Characteristic Celecoxib group (n = 122) Placebo group (n = 118) P*
Age, y    
  Mean (SD) 65.6 (9.9) 64.9 (10.4) .57
  Median (range) 66.4 (39.2–85.5) 65.8 (37.5–87.6)
Sex, No. (%)    
  Male 102 (84) 95 (81) .53
  Female 20 (16) 23 (19)
Race, No. (%)    
  White 121 (99) 118 (100) 1.00
  Other 1 ( 1) 0 (0)
Fitzpatrick skin type, No. (%)    
  I 18 (15) 20 (17) .82
  II 73 (60) 66 (56)
  III 31 (25) 32 (27)
Number of actinic keratoses at screening    
  Mean (SD) 24.2 (9.2) 23.6 (8.4) .58
  Median (range) 23.0 (10–46) 23.0 (11–41)
History of skin cancer, No. (%)    
  Yes 79 (65) 70 (59) .39
  No 43 (35) 48 (41)
Total number of skin cancer diagnoses per patient before screening, No. (%)
  0 43 (35) 48 (41) .56
  1 27 (22) 19 (16)
  2 18 (15) 21 (18)
  >2 34 (28) 30 (25)
  Mean (SD) 2.0 (2.5) 2.4 (5.1) .42
  Median (range) 1.0 (0–13) 1.0 (0–35)
Medical history of cardiovascular abnormalities,† No. (%) 67 (46) 47 (36) .11
Medical history of gastrointestinal abnormalities,‡ No. (%) 76 (51) 54 (40) .07
*  Based on two-sided t tests for continuous variables and two-sided x2 test or Fisher exact tests for categorical variables.
†  One patient in the placebo group had missing data.
‡  Two patients in the placebo group had missing data.jnci.oxfordjournals.org    JNCI | Articles 1839
The effect of treatment on the number of nonmelanoma skin 
cancers was evaluated by using Poisson regression and adjusting 
for patient time on study (Table 3). By month 11 after randomiza-
tion (or at early study withdrawal), the mean number of nonmela-
noma  skin  cancers  per  patient  was  statistically  significantly  less   
in  participants  who  received  celecoxib  than  in  participants   
who received placebo (0.14 vs 0.35; rate ratio [RR] = 0.43, 95%   
CI = 0.24 to 0.75, P = .003), representing a 60% reduction in the 
mean number of nonmelanoma skin cancers. A decrease in non-
melanoma skin cancers was also observed at month 9 after ran-
domization (Table 3). A difference in the number of nonmelanoma 
skin cancers between the two treatment groups was clearly evident 
by month 9 and was sustained for the rest of the time that the 
subjects were on the trial. In addition, we observed no rebound in 
the rate of development of nonmelanoma skin cancers in the cele-
coxib arm during the 2 months after subjects stopped taking cele-
coxib (Table 3). An inhibitory effect of celecoxib on nonmelanoma 
skin cancer development was also observed when cutaneous SCCs 
and BCCs were evaluated separately. By month 11 after randomi-
zation, the mean number of BCCs per patient in the celecoxib 
group was 0.07 (95% CI = 0.03 to 0.13) compared with 0.16 (95% 
CI = 0.1 to 0.25) in the placebo group (RR = 0.44; 95% CI = 0.19 
to 0.99; P = .049) (Table 3). By month 11 after randomization, the 
mean number of SCCs per patient was 0.07 (95% CI = 0.04 to 
0.14) in the celecoxib group compared with 0.19 (95% CI = 0.12 
to 0.28) in the placebo group (RR = 0.42; 95% CI = 0.19 to 0.92; 
P = .03) (Table 3).
The celecoxib treatment effect on skin cancer remained statis-
tically significant after adjusting for age, sex, Fitzpatrick skin type, 
actinic  keratosis  history  at  screening,  skin  cancer  history,  and   
log-transformed patient time on study. The adjusted rate ratios for 
the celecoxib arm compared with the placebo arm were 0.41 (95% 
CI = 0.23 to 0.72, P = .002) for nonmelanoma skin cancers, 0.40 
(95% CI = 0.18 to 0.93, P = .032) for BCCs, and 0.42 (95% CI = 
0.19 to 0.93, P = .032) for cutaneous SCCs. In subgroup analyses 
according to Fitzpatrick skin type (I, II, or III) and stratified by 
history of skin cancers and median number of actinic keratoses 
(≤23  vs  >23),  we  observed  no  statistically  significant  consistent 
difference between treatment arms with respect to nonmelanoma 
skin  cancers,  BCC,  or  SCC  among  subgroups  (Supplementary 
Table 1, available online), possibly reflecting the small number of 
subjects in several of the subgroups.
There was no statistically significant difference between those 
who remained in the study and those who withdrew with regard to 
any of the demographic or clinical characteristics (Table 4).
Four patients in the placebo group had three or more nonmela-
noma skin cancers compared with none in the celecoxib group 
(data not shown). One melanoma was diagnosed in the celecoxib 
group and none were diagnosed in the placebo group.
Safety
Eighty-four percent of celecoxib-treated subjects reported at least 
one adverse event compared with 85% of control subjects (P = .95) 
(Table 5). The most common adverse events were infections and 
infestations, followed by gastrointestinal, musculoskeletal, and skin 
disorders  and  hypertension  (a  frequent  side  effect  of  NSAIDs) 
(Supplementary Table 2, available online). The adverse effects that 
were more common in the celecoxib group than in the placebo 
group were those that are commonly attributed to cyclooxygenase 
446 Assessed for eligibility 
Withdrew from study 
Withdrew consent               7 (5.7%) 
Use of excluded medicine   3 (2.5%) 
Adverse event                    10 (8.2%) 
Lost to follow-up                 3 (2.5%) 
FDA termination                12 (9.9%) 
206 Excluded 
183 Did not meet inclusion criteria
  19 Refused to participate 
    4 Other reasons 
96 Completed study 
(81.4%)
87 Completed study 
(71.3%)
118 Received placebo 
(49.2%)
122 Received celecoxib 
(50.8%)
240 Randomly assigned
Withdrew from study 
Progression of disease        1 (0.9%) 
Withdrew consent               6 (5.1%) 
Use of excluded medicine   1 (0.9%) 
Adverse event                      6 (5.1%) 
Lost to follow-up                 2 (1.7%) 
FDA termination                  6 (5.1%) 
Figure 1. Study design and participant status by treatment arm. FDA = 
Food and Drug Administration.
Table 2. Effect of celecoxib on actinic keratoses at month 9*
Outcome variable Celecoxib group Placebo group P
Mean number of actinic keratoses per patient (95% CI)    
  At randomization 22.7 (21.1 to 24.3†) 22.2 (20.6 to 23.8) .67
  At the completion of therapy 17.9 (16.2 to 19.6) 18.1 (15.0 to 21.2) .95
Mean number of new actinic keratoses per patient  
  that had developed by the completion of therapy (95% CI)
8.5 (6.9 to 10.1) 9.6 (7.4 to 11.8) .43
Ratio of total lesions per patient at completion to  
  randomization lesions (95% CI)
0.81 (0.71 to 0.91) 0.78 (0.69 to 0.87) .66
Ratio of new lesions per patient at completion to  
  lesions at randomization (95% CI)
0.40 (0.32 to 0.48) 0.41 (0.35 to 0.47) .84
*  CI = confidence interval.
†  Two-sided t test.1840   Articles | JNCI  Vol. 102, Issue 24  |  December 15, 2010
inhibitors, that is, gastrointestinal disorders, skin rashes, hyperten-
sion, and hemorrhage. Serious events occurred in 16 subjects, nine 
of whom received celecoxib and seven of whom received placebo. 
This  difference  was  not  statistically  significant.  There  were  no 
deaths in either group.
Because cyclooxygenase 2 inhibitors have been reported (27) to 
increase the risk of serious cardiovascular adverse events (ie, myo-
cardial infarction, stroke, congestive heart failure, or cardiovascu-
lar deaths), we examined the occurrence of cardiovascular adverse 
events in greater detail (Table 5 and Supplementary Table 2, avail-
able online). A similar number of individuals experienced cardio-
vascular adverse events in the two treatment groups. There were 
nine adverse cardiovascular events in seven subjects treated with 
celecoxib compared with six adverse events in five subjects in the 
placebo  group.  The  number  of  subjects  in  the  two  treatment 
arms who experienced a cardiovascular event was not statistically 
significantly different.
Discussion
We found that compared with placebo, the cyclooxygenase 2 in-
hibitor celecoxib administered for 9 months was highly effective in 
preventing nonmelanoma skin cancers in subjects who had large 
numbers of actinic keratoses, some of whom had already developed 
one or more skin cancers, and thus were at high risk for these 
neoplasms (25,26). Our findings validate preclinical data that were 
the  premise  for  the  entry  of  celecoxib  into  clinical  testing 
(17,19,20,22). However, this analysis of nonmelanoma skin cancers 
should be considered exploratory because it was not the primary 
endpoint of the randomized trial.
This study was initiated because of preclinical evidence sug-
gesting that cyclooxygenase 2 is involved in the pathogenesis of 
sunlight-induced skin cancers (17–21). Specifically, expression of 
this enzyme is increased in the epidermis following UV exposure, 
and cyclooxygenase 2 can be detected in actinic keratoses and 
SCCs (17,19,22). In BCCs, cyclooxygenase 2 has been found in 
tumor islands and in the stroma surrounding the tumor islands 
(17). Moreover, cyclooxygenase 2 inhibitors have been successful 
at preventing UV-induced skin cancers in mouse models (17–21). 
There is also evidence from epidemiological studies that NSAIDs, 
which inhibit cyclooxygenases, are associated with a decreased 
risk  of  cutaneous  SCCs.  For  example,  in  a  case–control  study 
conducted  in  Australia,  subjects  who  had  taken  large  doses  of 
NSAIDs on a regular basis were less likely than subjects who had 
used NSAIDs infrequently or not at all to have had a cutaneous 
SCC (23). Another study (24) reported that among individuals 
Table 3. Mean number of nonmelanoma skin cancers, BCCs, and SCCs at each visit*
Type of lesion Study arm N
Mean number of tumors  
per patient (95% CI)† Rate ratio‡ (95% CI) P§
Month 3 visit        
  Nonmelanoma skin cancer Celecoxib 122 0.02 (0.01 to 0.08) 0.6 (0.14 to 2.49) .478
Placebo 118 0.04 (0.02 to 0.1)
  BCC Celecoxib 122 0 – –
Placebo 118 0.03 (0.01 to 0.08)
  SCC Celecoxib 122 0.025 (0.008 to 0.076) 1.49 (0.25 to 8.92) .662
Placebo 118 0.017 (0.004 to 0.068)
Month 6 visit        
  Nonmelanoma skin cancer Celecoxib 122 0.09 (0.05 to 0.16) 0.56 (0.27 to 1.16) .119
Placebo 118 0.17 (0.11 to 0.26)
  BCC Celecoxib 122 0.03 (0.01 to 0.09) 0.41 (0.13 to 1.29) .127
Placebo 118 0.08 (0.05 to 0.16)
  SCC Celecoxib 122 0.06 (0.03 to 0.12) 0.71 (0.27 to 1.86) .485
Placebo 118 0.08 (0.05 to 0.16)
Month 9 visit        
  Nonmelanoma skin cancer Celecoxib 122 0.12 (0.07 to 0.2) 0.48 (0.26 to 0.88) .018
Placebo 118 0.27 (0.19 to 0.38)
  BCC Celecoxib 122 0.07 (0.03 to 0.13) 0.68 (0.28 to 1.66) .398
Placebo 118 0.1 (0.06 to 0.18)
  SCC Celecoxib 122 0.06 (0.03 to 0.12) 0.36 (0.15 to 0.84) .019
Placebo 118 0.17 (0.11 to 0.26)
Month 11 visit        
  Nonmelanoma skin cancer Celecoxib 122 0.14 (0.09 to 0.22) 0.43 (0.24 to 0.75) .003
Placebo 118 0.35 (0.26 to 0.47)
  BCC Celecoxib 122 0.07 (0.03 to 0.13) 0.44 (0.19 to 0.99) .049
Placebo 118 0.16 (0.1 to 0.25)
  SCC Celecoxib 122 0.07 (0.04 to 0.14) 0.42 (0.19 to 0.92) .03
Placebo 118 0.19 (0.12 to 0.28)
*  At each visit or at time of early study withdrawal. BCC = basal cell carcinoma; SCC = squamous cell carcinoma; CI = confidence interval; – = not applicable.
†  The 95% confidence interval is based on Poisson distribution.
‡  Poisson regression adjusted for patient time on study.
§  Based on the Wald test in the Poisson regression models (two-sided).jnci.oxfordjournals.org    JNCI | Articles 1841
with  a  history  of  nonmelanoma  skin  cancers,  those  who  were 
NSAID users had a reduced risk of nonmelanoma skin cancers, in 
particular SCCs, compared with nonusers. However, the protec-
tive  effect  of  NSAIDs  on  nonmelanoma  skin  cancer  was  less 
striking in another study (38). In that study, in a cohort of high-
risk patients, subjects who used NSAIDs for less than the study 
duration  developed  fewer  BCCs  and  SCCs  than  subjects  who 
used NSAIDs for the entire length of the study (38). However, 
another retrospective case–control study (39) did not observe a 
statistically significant reduction in SCCs among individuals who 
reported taking any NSAID, ibuprofen, or nonaspirin NSAIDs. 
Similar conclusions were reached when pharmacy databases were 
examined for prescriptions for NSAID that were filled among 
patients with SCCs (39).
To our knowledge, no agents have been approved by either the 
FDA or governmental regulatory agents in other countries for the 
prevention of skin cancer. However, previous studies (11,40) that 
were based in Australia, where the skin cancer rates are the highest 
in the world, and conducted in the general population have con-
vincingly demonstrated that sunscreens are effective chemopre-
ventive  agents  for  actinic  keratoses  and  cutaneous  SCCs.  They 
showed that the regular use of an SPF15 sunscreen for more than 
5 years inhibited SCCs by approximately 35%, whereas the data 
for BCCs were limited (11,40). Despite the widespread use of sun-
screens for skin cancer prevention, appreciable numbers of these 
malignancies still occur. The findings of this study, which showed 
that the celecoxib-treated individuals developed fewer nonmela-
noma skin cancers than placebo-treated individuals, suggest that 
cyclooxygenase  inhibitors  may  provide  an  additional  benefit  to 
sunscreens in the prevention of nonmelanoma skin cancers.
There has been substantial interest in the use of cyclooxygenase 
inhibitors for the prevention of other types of cancer besides non-
melanoma skin cancers. For example, celecoxib has been shown in 
clinical trials to inhibit the formation of sporadic colorectal ade-
nomas and adenomas in familial adenomatous polyposis (41–43). 
Our results extend those findings to a second target organ system 
(ie, the skin) and to tumors caused by a different etiologic agent (ie, 
chronic  UV  exposure).  In  a  recent  study  (35)  that  examined 
NSAID  use  in  subjects  with  basal  cell  nevus  syndrome,  which 
Table 4. Baseline characteristics of patients who completed and withdrew from the study by treatment arm*
Characteristic
Celecoxib group Placebo group
Withdrew  
(n = 35)
Completed  
(n = 87) P
Withdrew  
(n = 22)
Completed  
(n = 96) P
Age, y          
  Mean (SD) 67.0 (11.1) 65.0 (9.5) .32 65.7 (9.0) 64.7 (10.7) .68
  Median (range) 68.4 (45.1–84.2) 65.9 (39.2–85.5)   64.1 (50.0–87.6) 66.5 (37.5–83.9)
Sex, No. (%)          
  Male 30 (86) 72 (83) .69 19 (86) 76 (79) .56
  Female 5 (14) 15 (17)   3 (14) 20 (21)
Race, No. (%)          
  White 35 (100) 86 (99) 1.00 22 (100) 96 (100) –
  Other 0 1 (1)   0 0
Fitzpatrick skin type, No. (%)       4 (18) 16 (17) .98
  I 8 (23) 10 (11) .25 12 (55) 54 (56)
  II 20 (57) 53 (61)   6 (27) 26 (27)
  III 7 (20) 24 (28)      
No. of actinic keratoses at screening
  Mean (SD) 23.8 (8.4) 24.4 (9.5) .74 24.1 (8.6) 23.5 (8.4) 0.75
  Median (range) 22 (10–41) 23 (10–46)   24 (12–38) 23 (11–41)
History of skin cancer, No. (%)          
  Yes 24 (69) 55 (63) .58 16 (73) 54 (56) .16
  No 11 (31) 32 (37)   6 (27) 42 (44)
Total number of skin cancer diagnoses per patient before screening, No. (%)
  0 11 (31) 32 (37) .86 6 (27) 42 (44) .17
  1 9 (26) 18 (21)   7 (32) 12 (12)
  2 6 (17) 12 (14)   4 (18) 17 (18)
  >2 9 (26) 25 (29)   5 (23) 25 (26)
  Mean (SD) 2.0 (2.6) 2.0 (2.4) .92 1.6 (1.8) 2.6 (5.6) .16
  Median (range) 1 (0–13) 1 (0–11)   1 (0–7) 1 (0–35)
*  P values from t tests for continuous variables and x2 tests or Fisher exact tests for categorical variables. All statistical tests were two-sided. – = not applicable.
Table 5. Adverse events in participants who received celecoxib or 
placebo
Type of  
adverse event
Celecoxib  
group
Placebo  
group P*
Any adverse event, No. of participants (%)
  0 19 (16)  18 (15) .95
  ≥1 103 (84) 100 (85)
Serious adverse event, No. of participants (%)
  No 113 (93) 111 (94) .65
  Yes 9 (7) 7 (6)
Cardiovascular adverse event, No. of participants (%)
  No 115 (94) 113 (96) .59
  Yes 7 (6) 5 (4)
*  Two-sided x
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predisposes individuals to develop large numbers of BCCs because 
of a genetic defect in the patched 1 gene (PTCH1) of the sonic 
hedgehog signal transduction pathway, among patients with fewer 
than 15 BCCs at study entry, those who received celecoxib for   
24 months developed statistically significantly fewer new BCCs 
than those treated with placebo.
Other agents have been evaluated for the chemoprevention of 
nonmelanoma skin cancer. Oral retinoid (44–46) and topical applica-
tion of the DNA repair enzyme T4 endonuclease V in liposomes (14) 
have both been shown to have chemopreventive activity against non-
melanoma skin cancers in patients with predisposing conditions, but 
neither has been tested in the general population. It is interesting that 
low-fat diets have also been reported to reduce the number of actinic 
keratoses and nonmelanoma skin cancers in clinical trials (16,47). 
However, compliance with such a restrictive diet could prove chal-
lenging for individuals placed on the diet. Thus, there is clearly a need 
for new interventions that prevent these common malignancies.
Celecoxib was effective at reducing the incidence of cutaneous 
SCC  but  did  not  prevent  its  precursor,  actinic  keratosis.  This 
finding was unexpected because results of preclinical studies on the 
prevention  of  SCC  in  mouse  models  suggested  that  celecoxib 
would reduce premalignant actinic keratoses as well as nonmela-
noma skin cancers (17,19–22). This preferential effect of celecoxib 
against later stages of tumor development is consistent with find-
ings of colorectal adenoma trials that tested celecoxib or aspirin 
(42,48,49). Although the precise mechanism for these unexpected 
results is not known, we envision three potential mechanisms by 
which  celecoxib  could  inhibit  the  progression  of  premalignant 
keratinocytes to invasive malignancies. First, cyclooxygenase 2 is 
required for the synthesis of prostaglandin E2, which stimulates the 
proliferation of malignant cells (50,51). Celecoxib could thus have 
an antiproliferative effect, possibly by promoting apoptosis. The 
antiproliferative effect has been invoked to explain the regression of 
colorectal adenomas in a placebo-controlled trial of celecoxib in 
patients with familial adenomatous polyposis (52,53). Second, my-
eloid suppressor cells, which promote invasion and angiogenesis of 
human BCC cells (54), require cyclooxygenase 2 for production of 
the immunosuppressive molecule arginase-1 (55). Celecoxib might 
render these cells less active and thereby inhibit the development of 
cutaneous SCCs and BCCs. Finally, celecoxib could suppress the 
epithelial–mesenchymal transition, a process through which malig-
nant cells weaken intercellular adhesions, thereby enhancing their 
motility and allowing them to penetrate into surrounding tissues. 
In lung carcinogenesis, it has been proposed that cyclooxygenase 2 
is intimately involved in this process (56).
The chemopreventive effect of celecoxib occurred rapidly. The 
numbers of new nonmelanoma skin cancers in the two treatment 
arms began to diverge within 3 months of the initiation of therapy 
for BCCs and within 6 months of the initiation of therapy for 
SCCs. This is not the first time that a chemopreventive agent has 
been shown to work this quickly to prevent BCCs: Kraemer et al. 
(45) observed an inhibitory effect on skin cancer development in 
xeroderma  pigmentosum  patients  within  3  months  of  adminis-
tering oral isotretinoin, and, a recurrence of nonmelanoma skin 
cancers within 3 months after oral isotretinoin was stopped. In this 
study,  nonmelanoma  skin  cancers  did  not  recur  during  the 
2-month follow-up period. However, the follow-up was short, and 
future studies will need to ascertain the durability of the response 
after cyclooxygenase inhibitors are discontinued.
Any beneficial effects of cyclooxygenase 2 inhibitors must be 
balanced against the adverse events associated with this class of 
compounds. Long-term use of rofecoxib (57) and of celecoxib (58) 
has  been  reported  to  increase  the  risk  of  serious  cardiovascular 
events. The risk of serious cardiovascular events appears to depend 
on the dose and duration of exposure, and in six randomized trials 
it was greatest in patients who had the highest risk of cardiovascular 
disease at baseline (59). In this study, there was no statistically sig-
nificant difference in the number of cardiovascular adverse events 
between  participants  who  received  celecoxib  and  those  who 
received placebo. However, participants in this study took celecoxib 
for  only  9  months,  whereas  increases  in  serious  cardiovascular 
adverse events with the cyclooxygenase 2 inhibitor rofecoxib were 
not observed until patients had taken it for 1 or more years (57).
The dose selected for this study—200 mg twice daily—is the 
same as that used to treat arthritis (60). It would be interesting to 
examine whether lower doses of celecoxib, an intermittent dosing 
regimen, or combination regimens are as effective as the dose used 
in this study but with fewer toxic effects. Alternatively, it is possible 
that chemoprevention of skin cancer could be achieved by topical 
application of a cyclooxygenase 2 inhibitor or a nonspecific cyclo-
oxygenase inhibitor (61).
The original intent of this trial was to examine the effect of 
celecoxib on actinic keratoses. Thus, one limitation of this study is 
that the effect of celecoxib on nonmelanoma skin cancers was not 
a  primary  or  secondary  endpoint.  Therefore,  additional  studies 
will need to be conducted in which the effect of cyclooxygenase 
inhibitors on nonmelanoma skin cancer development is the pri-
mary endpoint to confirm this observation. A second limitation is 
that  all  of  the  participants  in  this  study  had  extensive  actinic 
damage. It is unclear whether celecoxib would have the same effect 
in subjects with less actinic damage.
In conclusion, this study demonstrates that the cyclooxygenase 
2  inhibitor  celecoxib  is  an  effective  chemopreventive  agent  for 
nonmelanoma  skin  cancer  in  patients  who  are  at  high  risk  for   
the disease. It is possible that a combination of medications that 
include  sunscreens  as  well  as  cyclooxygenase  inhibitors  and/or 
other chemopreventive agents could be taken on a regular basis by 
individuals at risk for development of nonmelanoma skin cancers to 
reduce the incidence of this exceptionally common malignancy.
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